𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cardiac 123 I-metaiodobenzylguanidine scintigraphy in elderly depressed patients

✍ Scribed by Fujishiro, Hiroshige


Book ID
121758877
Publisher
John Wiley and Sons
Year
2014
Tongue
English
Weight
30 KB
Volume
68
Category
Article
ISSN
1323-1316

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Cardiac [123I]metaiodobenzylguanidine sc
✍ Joong-Seok Kim; Phil-Hyu Lee; Kwang-Soo Lee; Jeong-Wook Park; Yeong-In Kim; Yong πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 78 KB

## Abstract The purpose of our study was to prospectively evaluate cardiac [^123^I]metaiodobenzylguanidine (MIBG) uptake in patients with cerebrovascular disease (CVD) who develop clinical symptoms of vascular Parkinsonism (VP). A total of 19 consecutive patients who developed Parkinsonism during t

123I-metaiodobenzylguanidine scintigraph
✍ Olivier Rascol; Ludwig Schelosky πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 672 KB

## Abstract Autonomic dysfunction is common in Lewy body disorders (Parkinson's disease, Dementia with Lewy Bodies, Pure Autonomic Failure, and REM sleep disorder). The loss of post‐ganglionic myocardial sympathetic nerve fibers is a prominent feature of autonomic dysfunction in such disorders. ^12

Cardiac 123I-MIBG scintigraphy in patien
✍ Phil Hyu Lee; Ji Won Kim; Oh Young Bang; In Soo Joo; Seok-Nam Yoon; Kyoon Huh πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 81 KB

In some cases, it is difficult to differentiate essential tremor (ET) from Parkinson's disease (PD), especially in the early stages of the disease. We investigated cardiac sympathetic dysfunction using (123)I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy in 22 patients with ET, in compariso

Reply to Treglia et al.: 123I-metaiodobe
✍ Donald R. Royall πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 65 KB

Although we are sympathetic to Reynolds and Slocum's concerns, 1 their editorial errs on several points. The authors cite deference to regulatory (presumably Food and Drug Administration) approval as a constraint. The FDA has long recognized broad physician discretion in using FDAapproved drugs or d